EA201791950A1 - Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака - Google Patents

Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака

Info

Publication number
EA201791950A1
EA201791950A1 EA201791950A EA201791950A EA201791950A1 EA 201791950 A1 EA201791950 A1 EA 201791950A1 EA 201791950 A EA201791950 A EA 201791950A EA 201791950 A EA201791950 A EA 201791950A EA 201791950 A1 EA201791950 A1 EA 201791950A1
Authority
EA
Eurasian Patent Office
Prior art keywords
peptides
immunotherapy
pac
framework
combinations
Prior art date
Application number
EA201791950A
Other languages
English (en)
Other versions
EA037050B1 (ru
Inventor
Андреа Мар
Тони Вайншенк
Оливер Шоор
Дженс Фрицше
Харприт Сингх
Колетт Сонг
Original Assignee
Имматикс Байотекнолоджиз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имматикс Байотекнолоджиз Гмбх filed Critical Имматикс Байотекнолоджиз Гмбх
Publication of EA201791950A1 publication Critical patent/EA201791950A1/ru
Publication of EA037050B1 publication Critical patent/EA037050B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Изобретение относится к пептидам, белкам, нуклеиновым кислотам и клеткам для применения в иммунотерапевтических методах. В частности, настоящее изобретение относится к иммунотерапии рака. Настоящее изобретение относится далее к опухолеассоциированным пептидным эпитопам Т-клеток, в отдельности или в комбинации с другими опухолеассоциированными пептидами, которые могут, например, служить в качестве активных фармацевтических ингредиентов вакцинных композиций, стимулирующих противоопухолевые иммунные ответы, или стимулировать Т-клетки ex vivo с их перенесением в организм пациента. Пептиды, связанные с молекулами главного комплекса гистосовместимости (МНС), или пептиды в отдельности могут быть также мишенями антител, растворимых Т-клеточных рецепторов и других связывающих молекул.
EA201791950A 2015-03-31 2016-03-24 Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака EA037050B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562140767P 2015-03-31 2015-03-31
GBGB1505585.8A GB201505585D0 (en) 2015-03-31 2015-03-31 Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
PCT/EP2016/056601 WO2016156230A1 (en) 2015-03-31 2016-03-24 Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carcinoma (rcc) and other cancers

Publications (2)

Publication Number Publication Date
EA201791950A1 true EA201791950A1 (ru) 2018-02-28
EA037050B1 EA037050B1 (ru) 2021-01-29

Family

ID=53178474

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791950A EA037050B1 (ru) 2015-03-31 2016-03-24 Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака

Country Status (25)

Country Link
US (16) US9993536B2 (ru)
EP (4) EP3277310A1 (ru)
JP (3) JP7146399B2 (ru)
KR (2) KR20220070328A (ru)
CN (2) CN107438619B (ru)
AR (3) AR104114A1 (ru)
AU (5) AU2016240341B2 (ru)
BR (1) BR112017019804A2 (ru)
CA (1) CA2980814A1 (ru)
CL (5) CL2017002448A1 (ru)
CO (1) CO2017009616A2 (ru)
CR (3) CR20220163A (ru)
EA (1) EA037050B1 (ru)
GB (1) GB201505585D0 (ru)
HK (1) HK1247085A1 (ru)
IL (3) IL289444B (ru)
MA (5) MA41844A (ru)
MX (2) MX2017012504A (ru)
MY (1) MY181449A (ru)
PE (2) PE20180505A1 (ru)
PH (1) PH12017501651A1 (ru)
SG (2) SG11201707043WA (ru)
TW (5) TWI758912B (ru)
UA (1) UA124519C2 (ru)
WO (1) WO2016156230A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201601751A (zh) 2013-10-03 2016-01-16 Nitto Denko Corp 黏膜疫苗組合物
MX2016003325A (es) 2013-10-03 2016-07-06 Nitto Denko Corp Composicion de vacuna para mucosa.
EP3277685B1 (en) 2015-03-31 2021-01-13 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
JP7075125B2 (ja) 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
GB201609193D0 (en) 2016-05-25 2016-07-06 Immatics Biotechnologies Gmbh Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
CR20210129A (es) * 2017-01-27 2021-03-26 Immatics Biotechnologies Gmbh Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer (divisional exp. 2019-388)
DE102017115966A1 (de) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Polypeptidmolekül mit verbesserter zweifacher Spezifität
CA3069842A1 (en) 2017-07-14 2019-01-17 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
US20200347455A1 (en) * 2017-09-05 2020-11-05 Agency For Science, Technology And Research Clear Cell Renal Cell Carcinoma Biomarkers
KR20200087143A (ko) 2017-10-10 2020-07-20 그릿스톤 온콜로지, 인코포레이티드 핫스팟을 이용한 신생항원 동정
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
BR112020016176A2 (pt) 2018-02-09 2022-02-22 Immatics Us Inc Métodos de transdução de uma célula t, célula t transduzida geneticamente, composição farmacêutica, métodos de preparação de uma população de células t e uso da célula t
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
CN113874516A (zh) 2019-05-27 2021-12-31 伊玛提克斯美国公司 病毒载体及其在细胞过继疗法中的用途
KR20220018006A (ko) 2019-06-06 2022-02-14 이매틱스 바이오테크놀로지스 게엠베하 서열 유사 펩티드를 사용하는 계수기 선택에 의한 분류
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
KR20230012465A (ko) 2020-02-24 2023-01-26 이매틱스 유에스 인코포레이티드 암 및 관련 악성 종양을 치료하기 위해 t 세포를 확장하는 방법
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
DE102020106710A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN111413498B (zh) * 2020-04-08 2023-08-04 复旦大学附属中山医院 一种肝细胞肝癌的自身抗体7-AAb检测panel及其应用
TW202227616A (zh) 2020-08-21 2022-07-16 美商英麥提克斯股份有限公司 分離ｃｄ８＋選擇ｔ細胞的方法
KR20230135589A (ko) 2020-12-31 2023-09-25 이매틱스 유에스 인코포레이티드 Cd8 폴리펩타이드, 조성물 및 이의 사용 방법
BR112023022975A2 (pt) 2021-05-05 2024-01-23 Immatics Biotechnologies Gmbh Polipeptídeos de ligação ao antígeno bma031 melhorados
WO2023025851A1 (en) 2021-08-24 2023-03-02 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
WO2023044488A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
US20230192886A1 (en) 2021-11-08 2023-06-22 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
WO2023153763A1 (ko) * 2022-02-08 2023-08-17 고려대학교 산학협력단 C-met의 에피토프 및 hif1alpha의 에피토프를 포함하는 암 백신 및 이의 용도
WO2023212691A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. DOMINANT NEGATIVE TGFβ RECEPTOR POLYPEPTIDES, CD8 POLYPEPTIDES, CELLS, COMPOSITIONS, AND METHODS OF USING THEREOF
US20240066127A1 (en) 2022-04-28 2024-02-29 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348548A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof
US20230355678A1 (en) 2022-05-05 2023-11-09 Immatics US, Inc. Methods for improving t cell efficacy
CN115074445B (zh) * 2022-08-09 2023-08-08 河北医科大学第二医院 Eno3在肾癌诊断及治疗中的应用

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440859A (en) 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
JP2530801B2 (ja) 1978-12-22 1996-09-04 バイオゲン インコーポレイテッド 組換えｄｎａ分子
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4678751A (en) 1981-09-25 1987-07-07 Genentech, Inc. Hybrid human leukocyte interferons
US4766075A (en) 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US4582800A (en) 1982-07-12 1986-04-15 Hoffmann-La Roche Inc. Novel vectors and method for controlling interferon expression
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4677063A (en) 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
US4810648A (en) 1986-01-08 1989-03-07 Rhone Poulenc Agrochimie Haloarylnitrile degrading gene, its use, and cells containing the gene
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
GB2294267B (en) 1993-06-03 1996-11-20 Therapeutic Antibodies Inc Anti-TNFalpha Fab fragments derived from polyclonal IgG antibodies
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
CA2243235C (en) 1996-01-17 2010-08-10 Imperial College Innovations Limited Immunotherapy using cytotoxic t lymphocytes (ctl)
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
DE69738157T2 (de) * 1996-10-01 2008-05-08 Bio-Rad Laboratories, Inc., Hercules Polymorphismus und neue gene in der region des menschlichen hemochromatosisgens
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6934639B1 (en) 2000-02-25 2005-08-23 Wyeth Methods for designing agents that interact with MMP-13
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
IL151860A0 (en) 2000-03-27 2003-04-10 Technion Res & Dev Foundation Single chain class i major histocompatibility complexes, constructs encoding same and methods of generating same
AU7524601A (en) 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
US20070037165A1 (en) * 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030191073A1 (en) * 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
AU2002322280A1 (en) 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2003000012A2 (en) 2001-06-21 2003-01-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast and ovarian cancer
US7226594B2 (en) * 2001-11-07 2007-06-05 Agensys, Inc. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
WO2004033685A1 (en) 2002-10-09 2004-04-22 Avidex Ltd Single chain recombinant t cell receptors
AU2003263607A1 (en) * 2002-10-25 2004-05-13 Japan As Represented By The President Of The University Of Tokyo Method for diagnosing diffuse-type gastric cancer
AU2003276403B2 (en) 2002-11-09 2010-04-15 Adaptimmune Limited T cell receptor display
WO2004048599A2 (en) * 2002-11-22 2004-06-10 Incyte Corporation Transporters and ion channels
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
DE10313819A1 (de) * 2003-03-24 2004-10-07 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2005084116A2 (en) 2004-01-27 2005-09-15 Compugen Usa, Inc. Calcium channel variants
US7667001B1 (en) 2004-01-27 2010-02-23 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
US7569662B2 (en) 2004-01-27 2009-08-04 Compugen Ltd Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
DE602005016112D1 (de) 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe
ATE461215T1 (de) 2005-09-05 2010-04-15 Immatics Biotechnologies Gmbh Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
WO2007119515A1 (ja) * 2006-03-28 2007-10-25 Dainippon Sumitomo Pharma Co., Ltd. 新規腫瘍抗原ペプチド
WO2007114954A2 (en) * 2006-04-05 2007-10-11 Corixa Corporation Methods, compositions, and kits for the detection and monitoring of kidney cancer
US8586006B2 (en) 2006-08-09 2013-11-19 Institute For Systems Biology Organ-specific proteins and methods of their use
WO2008053573A1 (fr) 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
EP2565204B1 (en) 2007-07-27 2015-10-07 immatics biotechnologies GmbH Novel immunogenic epitopes for immunotherapy
US20090263574A1 (en) 2008-04-21 2009-10-22 Quinn Daniel E Method of restoring an article
FR2933304A1 (fr) * 2008-07-07 2010-01-08 Adocia Composition synergique osteogenique
US20110229451A2 (en) 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
WO2011097221A2 (en) * 2010-02-02 2011-08-11 Children's Medical Center Corporation Methods of promoting tissue growth and tissue regeneration
US10706955B2 (en) * 2010-03-23 2020-07-07 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
US20140170168A1 (en) 2010-10-26 2014-06-19 Yoram Reiter Antibodies which bind soluble t-cell receptor ligands
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US20120207743A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Retargeted Endopeptidases
US20120302573A1 (en) 2011-05-25 2012-11-29 Paul Francis Jackson Methods of inhibiting pro matrix metalloproteinase activation
TW201302800A (zh) * 2011-06-10 2013-01-16 Oncotherapy Science Inc Ｓｅｍａ５ｂ胜肽及含其之疫苗
WO2013057586A1 (en) 2011-10-19 2013-04-25 Oslo Universitetssykehus Hf Compositions and methods for producing soluble t - cell receptors
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
WO2013177533A1 (en) * 2012-05-25 2013-11-28 California Institute Of Technology Expression of secreted and cell-surface polypeptides
WO2014071978A1 (en) 2012-11-08 2014-05-15 Roche Diagnostics Gmbh Nucleic acids encoding chimeric polypeptides for library screening
WO2014087626A1 (en) * 2012-12-04 2014-06-12 Oncotherapy Science, Inc. Sema5b peptides and vaccines containing the same
EP2808392A1 (en) 2013-05-28 2014-12-03 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers and use of the aptamers in the diagnosis and treatment of cancer
TWI776192B (zh) 2013-08-05 2022-09-01 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（四）
JP6559227B2 (ja) * 2014-08-17 2019-08-14 セリベリー セラピューティクス，インコーポレーテッド 細胞透過性の改善のための進化型巨大分子伝達ドメイン（ａｄｖａｎｃｅｄ ｍａｃｒｏｍｏｌｅｃｕｌｅ ｔｒａｎｓｄｕｃｔｉｏｎ ｄｏｍａｉｎ）（ＡＭＴＤ）配列、それをコードするポリヌクレオチド、それを含むＡＭＴＤの固有の特性を同定する方法、それを含むＡＭＴＤ配列を開発する方法

Also Published As

Publication number Publication date
US10213498B2 (en) 2019-02-26
JP2018511321A (ja) 2018-04-26
BR112017019804A2 (pt) 2018-05-22
KR102451645B1 (ko) 2022-10-11
EA037050B1 (ru) 2021-01-29
JP2023061974A (ja) 2023-05-02
US20160289296A1 (en) 2016-10-06
US10314899B2 (en) 2019-06-11
AU2019201713B2 (en) 2020-06-04
SG11201707043WA (en) 2017-10-30
MA40794A1 (fr) 2019-05-31
UA124519C2 (uk) 2021-10-05
TW202231656A (zh) 2022-08-16
MA46304A (fr) 2019-07-31
PE20180505A1 (es) 2018-03-09
TW201639870A (zh) 2016-11-16
AR121383A2 (es) 2022-06-01
GB201505585D0 (en) 2015-05-13
CN107438619A (zh) 2017-12-05
AU2019201714B2 (en) 2020-04-02
CR20170440A (es) 2017-12-14
AU2019201713A1 (en) 2019-04-04
AU2020203850A1 (en) 2020-07-02
US9993536B2 (en) 2018-06-12
US10449240B2 (en) 2019-10-22
TW202116790A (zh) 2021-05-01
EP3517128A1 (en) 2019-07-31
US10835586B2 (en) 2020-11-17
TWI758243B (zh) 2022-03-21
CN113912702A (zh) 2022-01-11
AU2019201708B2 (en) 2020-11-26
AU2020203850B2 (en) 2022-04-14
MX2017012504A (es) 2018-01-18
MX2022000219A (es) 2022-02-03
MY181449A (en) 2020-12-22
EP3277310A1 (en) 2018-02-07
SG10202001834UA (en) 2020-04-29
US20180064796A1 (en) 2018-03-08
CL2021001776A1 (es) 2022-02-25
KR20220070328A (ko) 2022-05-30
US9931388B2 (en) 2018-04-03
CL2018003348A1 (es) 2019-01-18
JP7146399B2 (ja) 2022-10-04
TWI745127B (zh) 2021-11-01
MA46305A (fr) 2019-07-31
CR20220164A (es) 2022-05-05
JP2024028730A (ja) 2024-03-05
TWI756874B (zh) 2022-03-01
US20190091313A1 (en) 2019-03-28
MA46303A (fr) 2019-07-31
US20190314477A1 (en) 2019-10-17
US20210393756A1 (en) 2021-12-23
US10105428B2 (en) 2018-10-23
US20190269770A1 (en) 2019-09-05
US10363296B2 (en) 2019-07-30
IL285434A (en) 2021-09-30
US20190091314A1 (en) 2019-03-28
US20200147190A1 (en) 2020-05-14
TW202124411A (zh) 2021-07-01
US20160287687A1 (en) 2016-10-06
US20210275652A1 (en) 2021-09-09
KR20170132186A (ko) 2017-12-01
AU2019201708A1 (en) 2019-04-04
IL289444B (en) 2022-09-01
TW202116791A (zh) 2021-05-01
CA2980814A1 (en) 2016-10-06
AR121380A2 (es) 2022-06-01
AR104114A1 (es) 2017-06-28
AU2019201714A1 (en) 2019-04-04
US20220054612A1 (en) 2022-02-24
US10357552B2 (en) 2019-07-23
CL2023000812A1 (es) 2023-09-01
PE20231650A1 (es) 2023-10-17
CO2017009616A2 (es) 2018-02-09
IL285434B (en) 2022-02-01
CL2017002448A1 (es) 2018-03-16
AU2016240341A1 (en) 2017-09-07
CR20220163A (es) 2022-05-05
US11938176B2 (en) 2024-03-26
TWI758912B (zh) 2022-03-21
MA41844A (fr) 2018-02-06
US20180256693A1 (en) 2018-09-13
IL254204A0 (en) 2017-10-31
US20220040278A1 (en) 2022-02-10
EP3517126A1 (en) 2019-07-31
EP3517127A1 (en) 2019-07-31
WO2016156230A1 (en) 2016-10-06
HK1247085A1 (zh) 2018-09-21
US10478481B2 (en) 2019-11-19
US20190209670A1 (en) 2019-07-11
IL289444A (en) 2022-02-01
US20210030854A1 (en) 2021-02-04
PH12017501651A1 (en) 2018-03-12
US10548958B2 (en) 2020-02-04
US20180344826A1 (en) 2018-12-06
CN107438619B (zh) 2021-12-14
CL2019002663A1 (es) 2019-12-13
AU2016240341B2 (en) 2019-07-25
IL254204B (en) 2022-06-01

Similar Documents

Publication Publication Date Title
EA201791950A1 (ru) Новые пептиды и комбинации пептидов и каркасы для применения в иммунотерапии почечноклеточной карциномы (пкк) и других видов рака
EA201891116A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов рака
EA201890027A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии эпителиального рака яичника и других видов рака
EA201890440A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака предстательной железы и других видов рака
EA201792484A1 (ru) Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака
EA201890635A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии мелкоклеточного рака легких и других видов рака
EA201792632A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака
EA201891465A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии рака молочной железы и других видов рака
EA201792242A1 (ru) Новые пептиды и комбинации пептидов и их каркасы для применения в иммунотерапии колоректальной карциномы (крк) и других видов рака
EA201891699A2 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нескольких видов опухолей
EA201891638A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака
EA201891074A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии хлл и других видов рака
EA201792044A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
EA201791853A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака поджелудочной железы и других видов рака
EA201891701A1 (ru) Пептиды и комбинации пептидов для применения в иммунотерапии немелкоклеточного рака легких и других видов рака
EA201891874A3 (ru) Новые пептиды, комбинации пептидов и каркасы для применения в иммунотерапевтическом методе лечения различных видов рака
EA201891994A1 (ru) Лечение рака матки
MX2021013147A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra cancer de ovario y otros canceres.
EA201792531A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии и способы получения каркасов для применения при лечении рака поджелудочной железы и других видов рака
EA201792671A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака пищевода и других видов рака
EA201892333A1 (ru) Иммунотерапия меланомы и других видов рака
EA201892159A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии омл и других видов рака
MX2021001622A (es) Peptidos novedosos y combinacion de peptidos para usarse en inmunoterapia contra diferentes tumores.
PH12017502234A1 (en) Novel cell epitopes and combination of cell epitopes for use in the immunotherapy of myeloma and other cancers
EA201892499A1 (ru) Новые пептиды, комбинация пептидов в качестве мишеней и средств для применения в иммунотерапии рака желчного пузыря и холангиокарциномы и других видов рака